Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer
Status: | Active, not recruiting |
---|---|
Conditions: | Cervical Cancer, Cancer, Cancer, Endometrial Cancer |
Therapuetic Areas: | Oncology |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 3/14/2019 |
Start Date: | September 14, 2009 |
A Three Arm Randomized Phase II Study of Paclitaxel/Carboplatin/Bevacizumab (NSC #704865), Paclitaxel/Carboplatin/Temsirolimus (NSC #683864) and Ixabepilone (NSC #710428)/Carboplatin/Bevacizumab as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer
This randomized phase II trial studies paclitaxel, carboplatin, and bevacizumab or
paclitaxel, carboplatin, and temsirolimus or ixabepilone, carboplatin, and bevacizumab to see
how well they work in treating patients with stage III, stage IV, or recurrent endometrial
cancer. Drugs used in chemotherapy, such as paclitaxel, carboplatin, and ixabepilone, work in
different ways to stop the growth of tumor cells, either by killing the cells or by stopping
them from dividing. Monoclonal antibodies, such as bevacizumab, may interfere with the
ability of tumor cells to grow and spread. Temsirolimus may stop the growth of tumor cells by
blocking some of the enzymes needed for cell growth. It is not yet known which treatment
regimen is most effective in treating patients with endometrial cancer.
paclitaxel, carboplatin, and temsirolimus or ixabepilone, carboplatin, and bevacizumab to see
how well they work in treating patients with stage III, stage IV, or recurrent endometrial
cancer. Drugs used in chemotherapy, such as paclitaxel, carboplatin, and ixabepilone, work in
different ways to stop the growth of tumor cells, either by killing the cells or by stopping
them from dividing. Monoclonal antibodies, such as bevacizumab, may interfere with the
ability of tumor cells to grow and spread. Temsirolimus may stop the growth of tumor cells by
blocking some of the enzymes needed for cell growth. It is not yet known which treatment
regimen is most effective in treating patients with endometrial cancer.
PRIMARY OBJECTIVES:
I. To estimate the hazard of progression or death of each of the three arms relative to that
of historical controls in patients with advanced or recurrent endometrial cancer.
SECONDARY OBJECTIVES:
I. To determine the nature, frequency, and maximum degree of toxicity as assessed by Common
Terminology Criteria for Adverse Events (CTCAE) version (v)3.0 for each of the three arms.
II. To estimate the distribution of the duration of overall survival for each of the three
arms.
III. To estimate the proportion of patients with measurable disease who have confirmed
objective tumor responses by treatment.
TERTIARY OBJECTIVES:
I. Explore the associations between select biomarkers and progression-free survival as well
as secondary measures of clinical outcome (overall survival, tumor response, or disease
status if possible) in the context of histologic cell type and treatment.
IA. Somatic mutations in phosphatase and tensin homolog (PTEN)/ phosphoinositide-3-kinase
(PI3K) and RAS pathway members by Sequenom mutational profiling and targeted sequencing of
candidate genes.
IB. Microsatellite instability by analysis of five National Cancer Institute consensus
microsatellite markers (BAT25, BAT26, D2S2123, D5S346, and D17S250) using the Applied
Biosystems (ABI) Prism 3100 Genetic Analyzer.
IC. Copy number alterations (gains or losses) by array comparative genomic hybridization
(aCGH).
ID. Tumor expression of PTEN and class III beta-tubulin using immunohistochemistry.
IE. Concentration of vascular endothelial growth factor (VEGF) in pre-cycle 1 plasma using an
enzyme-linked immunosorbent assay.
II. Explore the relationship among the various biomarkers by histologic subtype and
treatment.
III. Explore which combination of biomarkers and clinical covariates optimally predicts
responsiveness and resistance to the three treatment arms.
OUTLINE: Patients are randomized to 1 of 3 treatment arms.
ARM I: Patients receive paclitaxel intravenously (IV) over 3 hours, carboplatin IV over 30
minutes, and bevacizumab* IV over 30-90 minutes on day 1. Treatment repeats every 21 days for
6 courses in the absence of disease progression or unacceptable toxicity.
MAINTENANCE THERAPY: Patients receive bevacizumab IV over 30-90 minutes on day 1. Treatment
repeats every 21 days in the absence of disease progression or unacceptable toxicity.
NOTE: *Patients undergoing treatment post-surgery (=< 12 weeks) receive bevacizumab beginning
on course 2.
ARM II: Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day
1 and temsirolimus* IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for 6
courses in the absence of disease progression or unacceptable toxicity.
MAINTENANCE THERAPY: Patients receive temsirolimus IV over 30 minutes on days 1, 8, and 15.
Treatment repeats every 21 days in the absence of disease progression or unacceptable
toxicity.
NOTE: *Patients undergoing treatment post-surgery (=< 12 weeks) receive temsirolimus
beginning on course 2.
ARM III: Patients receive ixabepilone IV over 1 hour, carboplatin IV over 30 minutes, and
bevacizumab* IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 courses in
the absence of disease progression or unacceptable toxicity.
MAINTENANCE THERAPY: Patients receive bevacizumab IV over 30-90 minutes on day 1. Treatment
repeats every 21 days in the absence of disease progression or unacceptable toxicity.
NOTE: *Patients undergoing treatment post-surgery (=< 12 weeks) receive bevacizumab beginning
on course 2.
After completion of study therapy, patients are followed up every 3 months for 2 years and
then every 6 months for 3 years.
I. To estimate the hazard of progression or death of each of the three arms relative to that
of historical controls in patients with advanced or recurrent endometrial cancer.
SECONDARY OBJECTIVES:
I. To determine the nature, frequency, and maximum degree of toxicity as assessed by Common
Terminology Criteria for Adverse Events (CTCAE) version (v)3.0 for each of the three arms.
II. To estimate the distribution of the duration of overall survival for each of the three
arms.
III. To estimate the proportion of patients with measurable disease who have confirmed
objective tumor responses by treatment.
TERTIARY OBJECTIVES:
I. Explore the associations between select biomarkers and progression-free survival as well
as secondary measures of clinical outcome (overall survival, tumor response, or disease
status if possible) in the context of histologic cell type and treatment.
IA. Somatic mutations in phosphatase and tensin homolog (PTEN)/ phosphoinositide-3-kinase
(PI3K) and RAS pathway members by Sequenom mutational profiling and targeted sequencing of
candidate genes.
IB. Microsatellite instability by analysis of five National Cancer Institute consensus
microsatellite markers (BAT25, BAT26, D2S2123, D5S346, and D17S250) using the Applied
Biosystems (ABI) Prism 3100 Genetic Analyzer.
IC. Copy number alterations (gains or losses) by array comparative genomic hybridization
(aCGH).
ID. Tumor expression of PTEN and class III beta-tubulin using immunohistochemistry.
IE. Concentration of vascular endothelial growth factor (VEGF) in pre-cycle 1 plasma using an
enzyme-linked immunosorbent assay.
II. Explore the relationship among the various biomarkers by histologic subtype and
treatment.
III. Explore which combination of biomarkers and clinical covariates optimally predicts
responsiveness and resistance to the three treatment arms.
OUTLINE: Patients are randomized to 1 of 3 treatment arms.
ARM I: Patients receive paclitaxel intravenously (IV) over 3 hours, carboplatin IV over 30
minutes, and bevacizumab* IV over 30-90 minutes on day 1. Treatment repeats every 21 days for
6 courses in the absence of disease progression or unacceptable toxicity.
MAINTENANCE THERAPY: Patients receive bevacizumab IV over 30-90 minutes on day 1. Treatment
repeats every 21 days in the absence of disease progression or unacceptable toxicity.
NOTE: *Patients undergoing treatment post-surgery (=< 12 weeks) receive bevacizumab beginning
on course 2.
ARM II: Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day
1 and temsirolimus* IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for 6
courses in the absence of disease progression or unacceptable toxicity.
MAINTENANCE THERAPY: Patients receive temsirolimus IV over 30 minutes on days 1, 8, and 15.
Treatment repeats every 21 days in the absence of disease progression or unacceptable
toxicity.
NOTE: *Patients undergoing treatment post-surgery (=< 12 weeks) receive temsirolimus
beginning on course 2.
ARM III: Patients receive ixabepilone IV over 1 hour, carboplatin IV over 30 minutes, and
bevacizumab* IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 courses in
the absence of disease progression or unacceptable toxicity.
MAINTENANCE THERAPY: Patients receive bevacizumab IV over 30-90 minutes on day 1. Treatment
repeats every 21 days in the absence of disease progression or unacceptable toxicity.
NOTE: *Patients undergoing treatment post-surgery (=< 12 weeks) receive bevacizumab beginning
on course 2.
After completion of study therapy, patients are followed up every 3 months for 2 years and
then every 6 months for 3 years.
Inclusion Criteria:
- Patients must have measurable stage III, measurable stage IVA, stage IVB (with or
without measurable disease) or recurrent (with or without measurable disease)
endometrial carcinoma
- Histologic confirmation of the original primary tumor is required; patients with
the following histologic epithelial cell types are eligible: endometrioid
adenocarcinoma, serous adenocarcinoma, undifferentiated carcinoma, clear cell
adenocarcinoma, mixed epithelial carcinoma, adenocarcinoma not otherwise
specified (N.O.S.), mucinous adenocarcinoma, squamous cell carcinoma, and
transitional cell carcinoma
- Measurable disease is defined by Response Evaluation Criteria in Solid Tumors (RECIST)
(version 1.1); measurable disease is defined as at least one lesion that can be
accurately measured in at least one dimension (longest diameter to be recorded); each
lesion must be >= 10 mm when measured by computed tomography (CT), magnetic resonance
imaging (MRI) or caliper measurement by clinical exam; or >= 20 mm when measured by
chest x-ray; lymph nodes must be >= 15 mm in short axis when measured by CT or MRI
- Patients must have Gynecologic Oncology Group (GOG) performance status of 0, 1, or 2
- Patients must not be eligible for a higher priority GOG protocol, if one exists; in
general, this would refer to any active GOG Phase III protocol or Rare Tumor protocol
for the same patient population
- Absolute neutrophil count (ANC) greater than or equal to 1,500/mcl equivalent to
Common Terminology Criteria (CTCAE v3.0) grade 1
- Platelets greater than or equal to 100,000/mcl
- Creatinine less than or equal to 1.5 times institutional upper limit normal (ULN),
CTCAE v3.0 grade 1
- Bilirubin less than or equal to 1.5 x ULN (CTCAE v3.0 grade 1)
- Serum glutamic oxaloacetic transaminase (SGOT) and serum glutamate pyruvate
transaminase (SGPT) less than or equal to 2.5 x ULN (CTCAE v3.0 grade 1)
- Alkaline phosphatase less than or equal to 2.5 x ULN (CTCAE v3.0 grade 1)
- Urine protein creatinine (UPC) ratio must be < 1.0 gram (gm); if UPC ratio >= 1,
collection of 24-hour urine measurement of urine protein is recommended (24-hour urine
protein level must be < 1000 mg for patient enrollment)
- UPC ratio of spot urine is an estimation of the 24 urine protein excretion
- A UPC ratio of 1 is roughly equivalent to a 24-hour urine protein of 1 gm
- Prothrombin time (PT) such that international normalized ratio (INR) is =< 1.5 x ULN
(or an in-range INR, usually between 2 and 3, if a patient is on a stable dose of
therapeutic warfarin) and a partial thromboplastin time (PTT) =< 1.5 x ULN
- Fasting cholesterol less than 300 mg/dL (CTCAE v3.0 grade 1)
- Fasting triglycerides =< 2.5 x ULN (CTCAE v3.0 grade 1)
- Patients must NOT have received prior chemotherapy or targeted therapy, including
chemotherapy used for radiation sensitization for treatment of endometrial carcinoma
- Patients must NOT have received prior therapy with bevacizumab or other VEGF pathway
targeted therapy; patients must NOT have received prior therapy with temsirolimus,
everolimus, ridaforolimus, sirolimus, or any other PI3K/ v-akt murine thymoma viral
oncogene homolog 1 (AKT)/mammalian target of rapamycins (mTor) pathway targeted
therapy
- Patients may have receive prior radiation therapy for treatment of endometrial
carcinoma; prior radiation therapy may have included pelvic radiation therapy,
extended field pelvic/para-aortic radiation therapy, and/or intravaginal
brachytherapy; all radiation therapy must be completed at least 4 weeks prior to the
first date of study therapy; the prior radiation field, radiation dose, number of
fractions and prior radiation start and stop dates must be provided on the Fast Fact
Sheet (FFS) at registration
- Patients may have received prior hormonal therapy for treatment of endometrial
carcinoma; all hormonal therapy must be discontinued at least one week prior to the
first date of study therapy
- Patients must have signed an approved informed consent and authorization permitting
release of personal health information
Exclusion Criteria:
- Patients with a history of other invasive malignancies, with the exception of
non-melanoma skin cancer, and other specific malignancies as noted below, are excluded
if there is any evidence of other malignancy being present within the last three
years; patients are also excluded if their previous cancer treatment contraindicates
this protocol therapy
- Patients who have received prior radiotherapy to any portion of the abdominal cavity
or pelvis OTHER THAN for the treatment of endometrial cancer within the last three
years are excluded; prior radiation for localized cancer of the breast, head and neck,
or skin is permitted, provided that it was completed more than three years prior to
registration, and the patient remains free of recurrent or metastatic disease
- Patients who have received prior chemotherapy for any abdominal or pelvic tumor within
the last three years are excluded; patients may have received prior adjuvant
chemotherapy for localized breast cancer, provided that it was completed more than
three years prior to registration, and that the patient remains free of recurrent or
metastatic disease
- Patients with serious, non-healing wound, ulcer, or bone fracture; this includes
history of abdominal/pelvic fistula, gastrointestinal perforation or intra-abdominal
abscess within 3 months prior to the first date of study therapy; patients with
underlying lesions that caused the fistula or perforation in the past that have not
been corrected
- Patients with active bleeding or pathologic conditions that carry high risk of
bleeding, such as known bleeding disorder, coagulopathy, or tumor involving major
vessels
- Patients with history or evidence upon physical examination of central nervous system
(CNS) disease, including primary brain tumor, seizures not controlled with standard
medical therapy or any brain metastases
- Patients with clinically significant cardiovascular disease; this includes:
- Uncontrolled hypertension, defined as systolic > 150 mm Hg or diastolic > 90 mm
Hg
- Myocardial infarction or unstable angina within 6 months of the first date of
study therapy
- New York Heart Association (NYHA) class II or greater congestive heart failure
- History of serious ventricular arrhythmia (i.e., ventricular tachycardia or
ventricular fibrillation) or cardiac arrhythmias requiring anti-arrhythmic
medications (except for atrial fibrillation that is well controlled with
anti-arrhythmic medication)
- CTCAE grade 2 or greater peripheral vascular disease.
- History of cerebrovascular accident (CVA, stroke), transient ischemic attack
(TIA) or subarachnoid hemorrhage within six months of the first date of study
therapy.
- Aortic aneurysm and/or history of aortic dissection
- Patients with known hypersensitivity to Chinese hamster ovary cell products or other
recombinant human or humanized antibodies
- Patients undergoing invasive procedures as defined below:
- Major surgical procedure, open biopsy or significant traumatic injury within 28
days prior to the first date of bevacizumab or temsirolimus therapy
- Major surgical procedure anticipated during the course of the study.
- Minor surgical procedures, fine needle aspirates, or core biopsies within 7 days
prior to the first date of study therapy
- Patients with known prior history of interstitial pneumonitis
- Patients with CTCAE v. 3, grade 2 or greater hypoxemia
- Patients with CTCAE v. 3, grade 2 or greater dyspnea
- Patients must not have uncontrolled diabetes, and must not have baseline hemoglobin
A1C (HgbA1C) > 8
- Patients with peripheral neuropathy > CTCAE v.3, grade 1
- Patients who are pregnant or nursing
We found this trial at
233
sites
Nebraska Methodist Hospital Methodist Hospital is a general medical and surgical hospital in Omaha, NE....
Click here to add this to my saved trials
1201 Camino de Salud Northeast
Albuquerque, New Mexico 87131
Albuquerque, New Mexico 87131
(505) 272-4946
University of New Mexico Cancer Center It’s been 40 years since the New Mexico State...
Click here to add this to my saved trials
Click here to add this to my saved trials
Roswell Park Cancer Institute Welcome to Roswell Park Cancer Institute (RPCI), America's first cancer center...
Click here to add this to my saved trials
1300 Jefferson Park Avenue
Charlottesville, Virginia 22908
Charlottesville, Virginia 22908
434-243-6784
University of Virginia Cancer Center We are fortunate in having state of the art clinical...
Click here to add this to my saved trials
166 Stoneridge Drive
Columbia, South Carolina 29210
Columbia, South Carolina 29210
803-461-3000
South Carolina Oncology Associates, PA South Carolina Oncology Associates (SCOA) is the only comprehensive cancer...
Click here to add this to my saved trials
Hurley Medical Center From its founding in 1908, Hurley Medical Center has devoted itself to...
Click here to add this to my saved trials
University of Texas Medical Branch Established in 1891 as the University of Texas Medical Department,...
Click here to add this to my saved trials
University of Mississippi Medical Center The University of Mississippi Medical Center, located in Jackson, is...
Click here to add this to my saved trials
Bronson Methodist Hospital Our healthcare system serves patients and families throughout southwest Michigan and northern...
Click here to add this to my saved trials
West Michigan Cancer Center In 1994, Borgess Health Alliance and Bronson Healthcare Group opened the...
Click here to add this to my saved trials
401 College Street
Richmond, Virginia 23298
Richmond, Virginia 23298
(804) 828-0450
Virginia Commonwealth University Massey Cancer Center Founded in 1974, VCU Massey Cancer Center is a...
Click here to add this to my saved trials
Click here to add this to my saved trials
1100 Fairview Avenue North
Seattle, Washington 98109
Seattle, Washington 98109
(206) 667-5000
Fred Hutchinson Cancer Research Center At Fred Hutchinson Cancer Research Center, our interdisciplinary teams of...
Click here to add this to my saved trials
Seattle Cancer Care Alliance Seattle Cancer Care Alliance (SCCA) is a cancer treatment center that...
Click here to add this to my saved trials
Avera Cancer Institute Avera, the health ministry of the Benedictine and Presentation Sisters, is a...
Click here to add this to my saved trials
601 South Sherman Street
Spokane, Washington 99202
Spokane, Washington 99202
(509) 228-1000
Cancer Care Northwest - Spokane South Cancer Care Northwest is the Inland Northwest’s premier cancer...
Click here to add this to my saved trials
Click here to add this to my saved trials
Abington Memorial Hospital Abington Memorial Hospital (AMH) is a 665-bed, regional referral center and teaching...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Saint Joseph Mercy Hospital St. Joseph Mercy Ann Arbor Hospital is a 537-bed teaching hospital...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
University of Colorado Hospital, Site Top medical professionals, superior medicine and progressive change make University...
Click here to add this to my saved trials
Click here to add this to my saved trials
Greater Baltimore Medical Center The 255-bed medical center (acute and sub-acute care) is located on...
Click here to add this to my saved trials
Sinai Hospital of Baltimore Sinai Hospital of Baltimore provides a broad array of high-quality, cost-effective...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Cancer Center of Kansas, PA - Chanute Dr. H.E. Hynes founded Cancer Center of Kansas,...
Click here to add this to my saved trials
171 Ashley Avenue
Charleston, South Carolina 29425
Charleston, South Carolina 29425
843-792-1414
Medical University of South Carolina The Medical University of South Carolina (MUSC) has grown from...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Rush University Medical Center Rush University Medical Center encompasses a 664-bed hospital serving adults and...
Click here to add this to my saved trials
Click here to add this to my saved trials
5841 S Maryland Ave
Chicago, Illinois 60637
Chicago, Illinois 60637
1-773-702-6180
University of Chicago Comprehensive Cancer Center The University of Chicago Comprehensive Cancer Center (UCCCC) is...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
18101 Lorain Avenue
Cleveland, Ohio 44111
Cleveland, Ohio 44111
216.476.7000
Cleveland Clinic Cancer Center at Fairview Hospital Fairview Hospital is a 488-bed hospital located at...
Click here to add this to my saved trials
Case Western Reserve Univ Continually ranked among America's best colleges, Case Western Reserve University has...
Click here to add this to my saved trials
MetroHealth Med Ctr The MetroHealth System is one of the largest, most comprehensive health care...
Click here to add this to my saved trials
Cleveland Clinic Foundation The Cleveland Clinic (formally known as The Cleveland Clinic Foundation) is a...
Click here to add this to my saved trials
Mercy Cancer Center - West Lakes When it comes to cancer care, there
Click here to add this to my saved trials
Click here to add this to my saved trials
University of Missouri-Ellis Fischel Ellis Fischel Cancer Center's team of physician specialists and other trained...
Click here to add this to my saved trials
Click here to add this to my saved trials
Riverside Methodist Hospital Serving central Ohio since 1892, Riverside Methodist Hospital is consistently ranked one...
Click here to add this to my saved trials
Click here to add this to my saved trials
Parkland Memorial Hospital As our community's public health system, Parkland is the foundation for a...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Geisinger Medical Center Since 1915, Geisinger Medical Center has been known as the region’s resource...
Click here to add this to my saved trials
Miami Valley Hospital Miami Valley Hospital (MVH) is passionate about providing the most recent medical...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Mercy Medical Center - Des Moines Mercy Medical Center
Click here to add this to my saved trials
Iowa Methodist Medical Center Iowa Methodist Medical Center was established in 1901 in a single...
Click here to add this to my saved trials
Iowa Lutheran Hospital Iowa Lutheran Hospital has a long history of serving the Des Moines...
Click here to add this to my saved trials
Click here to add this to my saved trials
Cancer Center of Kansas, PA - Dodge City Dr. H.E. Hynes founded Cancer Center of...
Click here to add this to my saved trials
Duke Univ Med Ctr As a world-class academic and health care system, Duke Medicine strives...
Click here to add this to my saved trials
Cancer Center of Kansas, PA - El Dorado Dr. H.E. Hynes founded Cancer Center of...
Click here to add this to my saved trials
Click here to add this to my saved trials
Michiana Hematology-Oncology The Advanced Center for Cancer Care in Plymouth is part of the Cancer...
Click here to add this to my saved trials
Elkhart Clinic, LLC Informed participation in the management of your health care maximizes your Elkhart...
Click here to add this to my saved trials
Elkhart General Hospital For over 100 years, the highly skilled professionals of Elkhart General Hospital...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Providence Regional Cancer Partnership Founded in 2007, the Providence Regional Cancer Partnership is the result...
Click here to add this to my saved trials
420 S Saginaw St
Flint, Michigan 48502
Flint, Michigan 48502
810-232-3522
Genesys Regional Medical Center-West Flint Campus The health care team at Genesys Downtown Flint Health...
Click here to add this to my saved trials
Cancer Center of Kansas - Fort Scott Dr. H.E. Hynes founded Cancer Center of Kansas,...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
The Hartford Hospital Hartford Hospital is the major teaching hospital affiliated with the University of...
Click here to add this to my saved trials
Click here to add this to my saved trials
500 University Dr
Hershey, Pennsylvania 17033
Hershey, Pennsylvania 17033
(717) 531-6955
Penn State Milton S. Hershey Medical Center Penn State Milton S. Hershey Medical Center, Penn...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
1319 Punahou St
Honolulu, Hawaii 96826
Honolulu, Hawaii 96826
(808) 983-6000
Kapiolani Medical Center for Women and Children Hawai‘i Pacific Health is an integrated health care...
Click here to add this to my saved trials
Straub Clinic And Hospital Founded in 1921, Straub Clinic & Hospital is a fully integrated...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Queen's Medical Center The Queen's Medical Center, located in downtown Honolulu, Hawaii, is a private,...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials